Avantor completes $900M term loan amendment to fund Curie acquisition; appoints Mala Murthy to board

Avantor, Inc.

Obtained $900M in incremental B-5 term loans at LIBOR+2.25% (0.50% floor), maturing Nov 2027.
Proceeds used to fund acquisition of Curie Holdings, LLC and refinance existing Curie debt.
Mala Murthy, CFO of Teladoc Health, appointed as Class I independent director effective Dec 1, 2021.
Murthy to serve on Audit and Finance Committee; receives standard non-employee director compensation.

item 1.01 item 2.03 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mala Murthy

Class I director

AVTR · Avantor, Inc.

Effective: 2021-12-01
Filed: November 2, 2021, 7:59 PM ET

On October 28, 2021, the Board, upon the recommendation of its Nominating and Governance Committee, appointed Mala Murthy as a Class I director with an initial term expiring at the Company’s 2022 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mala Murthy was appointed as Class I director at Avantor, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On October 28, 2021, the Board, upon the recommendation of its Nominating and Governance Committee, appointed Mala Murthy as a Class I director with an initial term expiring at the Company’s 2022 Annual Meeting of Stockholders.

View on SEC.gov

Avantor, Inc. filing history →

Source: SEC EDGAR

accession 0001722482-21-000257

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.